Umecrine Cognition

Hepatic Encephalopathy is a significant and increasing health care problem due to the large and increasing epidemics of chronic liver disease.

Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (GABA-steroids). The company is focused on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease, a growing area with high unmet medical need.